CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Monday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Up 1.0 %

Shares of NYSE CVM opened at $0.24 on Monday. The stock has a market cap of $19.34 million, a PE ratio of -0.50 and a beta of 0.95. CEL-SCI has a 52-week low of $0.18 and a 52-week high of $2.39. The business has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.54. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC raised its stake in CEL-SCI Co. (NYSE:CVM) by 40.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned 0.26% of CEL-SCI worth $76,000 at the end of the most recent reporting period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.